SuperworthPyxis Oncology market cap PYXS
Share price times shares outstanding: what the whole company sells for, since 2021.
- Today, Oct 23, 2026
- $140.1M
- Highest close in our data
- $423.3M
- Nov 2021
Pyxis Oncology is worth $140.1M at the close on Oct 23, 2026, at $1.68 a share.
That is down 35% over the last year and down 67% over five years.
Its highest close in our data was $423.3M in Nov 2021.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $140.1M | $71.6M | $324.5M | +103% |
| 2025 | $69.1M | $56.1M | $323.2M | −27% |
| 2024 | $94.6M | $93.5M | $317.4M | +19% |
| 2023 | $79.8M | $50.9M | $148.3M | +70% |
| 2022 | $47M | $40.7M | $337.5M | −87% |
| 2021 | $359.4M | $278.5M | $423.3M | n/a |
Against its peers
Companies in Drug Manufacturers - General nearest Pyxis Oncology's size, closest first, today.
| Company | Market cap |
|---|---|
| PYXSPyxis Oncology | $140.1M |
| NATRNatures Sunshine Products | $213.8M |
| LFVNLifevantage | $73.4M |
| SPROSpero Therapeutics | $64.6M |
| ATNMActinium Pharmaceuticals | $47.8M |
| ARVNArvinas | $477.3M |
| PBYIPuma Biotechnology | $568.9M |
| IRWDIronwood Pharmaceuticals | $571.7M |
| ZVRAZevra Therapeutics | $582.6M |
| CRMDCorMedix | $611.9M |
| COLLCollegium Pharmaceutical | $747.5M |
| Peer median | $523.1M |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on Pyxis Oncology
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.